

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A live adenovirus formulation comprising 0.25% to 0.6% (w/v) chlorobutanol and a buffer within a pH range of ~~about~~ 6.0 to ~~about~~ 9.0.
2. (previously presented) A live adenovirus formulation of claim 1 wherein the formulation contains from 0.4% to 0.6% (w/v) chlorobutanol.
3. (original) A live adenovirus formulation of claim 1 wherein the formulation further comprises at least one inhibitor of free radical oxidation.
4. (previously presented) A live adenovirus formulation of claim 3 wherein the formulation contains from 0.4% to 0.6% (w/v) chlorobutanol.
5. (original) A live adenovirus formulation of claim 3 wherein the inhibitor of free radical oxidation is selected from the group consisting of EDTA, ethanol, histidine, or combinations thereof.
6. (previously presented) A live adenovirus formulation of claim 5 wherein the formulation contains from 0.4% to 0.6% (w/v) chlorobutanol.
7. (previously presented) A live adenovirus formulation of claim 5 wherein the formulation further comprises a cryoprotectant, a salt, a divalent cation, and a non-ionic detergent.
8. (previously presented) A live adenovirus formulation of claim 7 wherein the formulation contains from 0.4% to 0.6% (w/v) chlorobutanol.
9. (original) A live adenovirus formulation of claim 1 with an adenovirus concentration in the range from about 1×10^7 vp/mL to about 1×10^{13} vp/mL and a total osmolarity in a range from about 200 mOs/L to about 800 mOs/L.

10. (previously presented) A live adenovirus formulation of claim 9 wherein the formulation contains from 0.4% to 0.6% (w/v) chlorobutanol.

11-20. (canceled)

21. (currently amended) A filled multi-dose vaccine vial comprising live adenovirus, 0.25% to 0.6% (w/v) chlorobutanol, and a buffer within a pH range of ~~about~~ 6.0 to ~~about~~ 9.0.

22. (previously presented) The multi-dose vaccine vial of claim 21 wherein the formulation contains from 0.4% to 0.6% (w/v) chlorobutanol.

23. (original) The multi-dose vaccine vial of claim 21 wherein the formulation further comprises at least one inhibitor of free radical oxidation.

24. (previously presented) The multi-dose vaccine vial of claim 23 wherein the formulation contains from 0.4% to 0.6% (w/v) chlorobutanol.

25. (previously presented) The multi-dose vaccine vial of claim 23 wherein the inhibitor of free radical oxidation is selected from the group consisting of EDTA, ethanol, histidine, or combinations thereof.

26. (previously presented) The multi-dose vaccine vial of claim 25 wherein the formulation contains from 0.4% to 0.6% (w/v) chlorobutanol.

27. (previously presented) The multi-dose vaccine vial of claim 25 wherein the formulation further comprises a cryoprotectant, a salt, a divalent cation, and a non-ionic detergent.

28. (previously presented) The multi-dose vaccine vial of claim 27 wherein the formulation contains from 0.4% to 0.6% (w/v) chlorobutanol.

29. (original) The multi-dose vaccine vial of claim 21 with an adenovirus concentration in the range from about 1×10^7 vp/mL to about 1×10^{13} vp/mL and a total osmolarity in a range from about 200 mOs/L to about 800 mOs/L.

30. (previously presented) The multi-dose vaccine vial of claim 29 wherein the formulation contains from 0.4% to 0.6% (w/v) chlorobutanol.

31. (currently amended) A method of preserving a live adenovirus formulation which comprises adding a) chlorobutanol to the formulation to a concentration of 0.25% to 0.6% (w/v) and b) a buffer within a pH range of ~~about~~ 6.0 to ~~about~~ 9.0, such that addition of chlorobutanol maintains adequate antimicrobial effectiveness while maintaining stability of the adenovirus for at least one year when stored at 2-8°C.

32. (previously presented) The method of claim 31 wherein the formulation contains from 0.4% to 0.6% (w/v) chlorobutanol.

33-36. (canceled)

37. (new) The live adenovirus formulation of claim 1 wherein the buffer has a pH within a pH range of 6.4 to 7.4.

38. (new) The live adenovirus formulation of claim 37 wherein the formulation contains from 0.4% to 0.6% (w/v) chlorobutanol.

39. (new) The multi-dose vaccine vial of claim 21 wherein the buffer has a pH within a pH range of 6.4 to 7.4.

40. (new) The multi-dose vaccine vial of claim 39 wherein the formulation contains from 0.4% to 0.6% (w/v) chlorobutanol.

41. (new) The method of claim 31 wherein the buffer has a pH within a pH range of 6.4 to 7.4.

42. (new) The method of claim 41 wherein the formulation contains from 0.4% to 0.6% (w/v) chlorobutanol.